R&D Systems' RANKL 蛋白介紹
RANKL:
更正:R&D RANKL蛋白氨基酸長度為182個,不是之前所說245個。
別名:“腫瘤壞死因子配體超家族成員11”(tumor necrosis factor ligand superfamily member 11,TNFSF11)、“腫瘤壞死因子相關誘導細胞因子”(TNF-related activation-induced cytokine,TRANCE)、“蝕骨細胞抑制因子配體”(osteoprotegerin ligand,OPGL)或蝕骨細胞分化因子(osteoclast
differentiation factor,ODF)。
結構:RANKL是腫瘤壞死因子(tumor necrosis
factor,TNF)超家族的一員,為破骨細胞抑制因子(osteoprotegerin)的配體,他是造骨細胞(osteoblast)膜上的一種膜蛋白,屬于一種Ⅱ型跨膜蛋白。The human RANK Ligand cDNA encodes a type II transmembrane protein of 317 amino acids with a predicted cytoplasmic domain of 47 amino acids, a 21 amino acids transmembrane region, and an extracellular domain of 249 amino acids.
作用機理:
A.
成骨細胞及骨髓基質細胞表達的RANKL與破骨細胞前體細胞或破骨細胞表面上的RANK結合,RANK膜內區有3個結合位點,與TNFR相關因子(TNF receptor associate factors, TRAFs)中的RAF1、2、3、5及6結合后,可激活轉錄因子NF-kB和蛋白激酶JNK,從而促進破骨細胞的分化及骨吸收活性。
B.
OPG(骨保護素)作為一種誘騙受體,可以競爭性的與RANKL結合,從而封閉RANKL與破骨細胞表面的RANK結合,抑制破骨細胞的分化成熟。
C.
RANKL/RANK與RANKL/OPG在生物體內保持著一定的比率,如果比率失衡,就會引起各種骨疾病。RANKL/RANK與RANKL/OPG系統將骨代謝、免疫系統和內分泌系統緊密的聯系起來,為骨質疏松、類風濕關節炎、骨腫瘤及腫瘤的骨轉移等骨破壞性疾病的治療開辟了新的途徑。
RANKL作用:
A.
可以增強成熟蝕骨細胞的活力,阻止破骨細胞凋亡,RANKL過表達,可導致一系列骨疾病,如風濕性關節炎,銀屑病性關節炎。實驗發現,將TNFSF基因剔除掉的老鼠,會導致嚴重的骨質石化癥(Osteopetrosis),且會缺乏蝕骨細胞
B.
免疫上,RANKL被視為是樹突細胞的存活因子。RANKL可阻止樹突細胞凋亡,促進T淋巴細胞增殖,且在淋巴細胞的早期發育和淋巴結的器官發育中發揮決定性的作用,這些作用可被OPG阻斷。這些都提示OPG/RANK/RANKL系統可能是聯系骨代謝與免疫系統之間的橋梁。
C.
RANKL也可能具有調節細胞凋亡的功能。RANKL還可以透過與“SRC激酶”(SRC kinase),以及“腫瘤壞死因子受體相關因子6”(tumor necrosis factor receptor-associated factor 6,TRAF6)形成信息復合物,以致活AKT/PKB等細胞凋亡抑制激酶。
應用:
A. 骨代謝方面,如骨質疏松癥,風濕性關節炎等相關。
B. 免疫相關
C. 癌癥
RANKL蛋白因子使用方法:
在使用貨號為390-TN-010的RANKL蛋白誘導細胞分化時,培養基中需同時加入抗His-tag標簽抗體:Mouse Anti-polyHistidine Monoclonal Antibody (Catalog # MAB050)。只有此抗體存在時RANKL配體才能形成聚合體,進一步發揮功能
競爭分析:R&D VS
PEPROTECH
R&D
Recombinant Human RANCE/TNFSF11/RANK L
|
|
|||
DESCRIPTION |
CATALOG # |
SIZE |
Price |
|
Recombinant Human TRANCE/RANK L/TNFSF11 |
10 μg |
4,150.00 |
||
Recombinant Human TRANCE/RANK L/TNFSF11, CF |
390-TN-010/CF |
10 μg |
4,150.00 |
|
Source:Mouse myeloma cell line, NS0-derived
Accession #:AAC51762
N-terminal Sequence Analysis:Met
Purity:>90%, by SDS-PAGE under reducing
conditions and visualized by silver stain.
Predicted Molecular Mass:23 kDa
SDS-PAGE:35 kDa, reducing conditions
Activity:Measured by its ability to induce
osteoclast differentiation of RAW 264.7 mouse monocyte/macrophage cells.The ED50 for this effect is typically 1.5-7.5 ng/mL in the presence of 2.5 μg/mL of a cross-linking antibody,
Protein Construct:
MHHHHHHHHHH |
GGGSGGGSGGGS |
IEGR |
Human
TRANCE |
N-terminus |
C-terminus |
AA Sequence:182aa
65 qhira ekamvdgswl dlakrsklea qpfahltina tdipsgshkv slsswyhdrg
121 wgkisnmtfs ngklivnqdg
fyylyanicf rhhetsgdla teylqlmvyv tktsikipss
181 htlmkggstk ywsgnsefhf
ysinvggffk lrsgeeisie vsnpslldpd qdatyfgafk
241 vrdid
Recombinant Human sRANK Ligand
Catalog Number: 310-01price:2340
20.0 kDa polypeptide comprising the TNF homologous region of RANKL (176 amino acid residues).
AA Sequence: 176aa
MEKAMVDGSW LDLAKRSKLE AQPFAHLTIN ATDIPSGSHK VSLSSWYHDR GWAKISNMTF SNGKLIVNQD GFYYLYANIC FRHHETSGDL ATEYLQLMVY VTKTSIKIPS SHTLMKGGST KYWSGNSEFH FYSINVGGFF KLRSGEEISI EVSNPSLLDP DQDATYFGAF KVRDID
Biological Activity:
Determined by its
ability to induce NFkappaB in RAW264.7 cells in the absence of any cross-linking. The expected ED50 for this effect is 10.0-25.0 ng/ml
R&D優勢:
優勢 |
ED50(3倍) |
His-Tag標簽* |
R&D |
1.5-7.5 ng/mL |
含有His-Tag標簽 |
Peprotech |
10.0-25.0
ng/ml |
無HHis-Tag標簽 |
*RANKL與其受體RANK以六聚體的形式結合并將信號傳遞至NF-κB,若無His-Tag標簽,RANKL不能聚合成聚合體的結構而發揮功能。
延伸:
許多激素和細胞因子參與調節RANKL的表達。IL-1、IL-17、1,25(OH)2D3、PTH、糖皮質激素和PGE2都可促進RANKL的表達,而TGF-B則抑制其表達。體外實驗證實,RANKL和M-CSF可取代OB/ST誘導多能破骨祖細胞分化成熟。
Mouse Anti-polyHistidine Monoclonal Antibody (Catalog # MAB050)
DESCRIPTION |
ANTIBODY |
CATALOG # |
SIZE |
PRICE |
His Tag MAb (Clone AD1.1.10), Mouse IgG1 |
AP, WB |
500 μg |